Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: A prospective longitudinal observational cohort study

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Arends, Suzanne ^a   Brouwer, Elisabeth ^a   van der Veer, Eveline ^a   Groen, Henk ^a   Leijsma, Martha K ^a   Houtman, Pieternella M ^b   Th A Jansen, Tim L ^b   Kallenberg, Cees G M ^a   Spoorenberg, Anneke ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGE; ANKYLOSING SPONDYLITIS; ARTICLE; ASSESSMENTS IN ANKYLOSING SPONDYLITIS; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BLADDER CANCER; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DEMYELINATING DISEASE; DIARRHEA; DISEASE ACTIVITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GENDER; HUMAN; INFECTION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALAISE; MALE; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RECURRENT INFECTION; TREATMENT RESPONSE; UVEITIS; DRUG ANTAGONISM; HOSPITALIZATION; MIDDLE AGED; PREDICTIVE VALUE; WITHDRAWAL SYNDROME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; SUBSTANCE WITHDRAWAL SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959260432     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3369     Document Type: Article

References (25)

1. Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, van der Heijde D. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008, 59:1270-1278. 10.1002/art.24001, 18759257.
2. Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola EM, Paolozzi L, Salvarani C, Sanmarti R, Sibilia J, Sieper J, Van den Bosch F, van der Heijde D, van der Linden S, Wajdula J. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009, 36:1256-1264. 10.3899/jrheum.081033, 19411393.
3. van der Heijde D, Schiff MH, Sieper J, Kivitz AJ, Wong RL, Kupper H, Dijkmans BA, Mease PJ, Davis JC. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009, 68:922-929. 10.1136/ard.2007.087270, 2674550, 18701556.
4. Davis JC, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, Inman RD, de Vries T, Tsuji W. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005, 32:1751-1754.
5. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004, 63:665-670. 10.1136/ard.2003.016386, 1755042, 15037444.
6. Rudwaleit M, Claudepierre P, Wordsworth P, Cortina EL, Sieper J, Kron M, Carcereri-De-Prati R, Kupper H, Kary S. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009, 36:801-808. 10.3899/jrheum.081048, 19273449.
7. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010, 69:2002-2008. 10.1136/ard.2009.124446, 20511613.
8. Lord PA, Farragher TM, Lunt M, Watson KD, Symmons DP, Hyrich KL. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010, 49:563-570.
9. Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P. Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res 2010, 62:1362-1369.
10. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, van der Linden S, van der Heijde D. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:18-24.
11. van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewe R. The ASDAS is a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2008, 68:1811-1818.
12. Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landewe R, Maksymowych W, van der Heijde D. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009, 68(Suppl 2):1-44.
13. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006, 65:316-320. 10.1136/ard.2005.040758, 1798064, 16096329.
14. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994, 21:2286-2291.
15. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994, 21:2281-2285.
16. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44:1876-1886. 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F, 11508441.
17. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921-926. 10.1136/ard.2006.065615, 1955110, 17301106.
18. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715. 10.1002/art.21671, 16508927.
19. Atzeni F, Antivalle M, Pallavicini FB, Caporali R, Bazzani C, Gorla R, Favalli EG, Marchesoni A, Sarzi-Puttini P. Predicting response to anti-TNF treatment in rheumatoid arthritis patients. Autoimmun Rev 2009, 8:431-437. 10.1016/j.autrev.2009.01.005, 19211043.
20. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006, 45:1558-1565.
21. Carmona L, Gomez-Reino JJ. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006, 8:R72. 10.1186/ar1941, 1526631, 16620398.
22. Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, Kvien TK. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008, 59:234-240. 10.1002/art.23333, 18240258.
23. Konttinen L, Tuompo R, Uusitalo T, Luosujarvi R, Laiho K, Lahteenmaki J, Puurtinen-Vilkki M, Lanteri R, Kortelainen S, Karilainen H, Varjolahti-Lehtinen T, Nordstrom D. Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience. Clin Rheumatol 2007, 26:1693-1700. 10.1007/s10067-007-0574-5, 17332979.
24. Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ, Brouwer E. The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010, 28:661-668.
25. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:531-535. 10.1136/ard.2008.089979, 18375542.